

13 August 2024

**Aptamer Group plc**

**("Aptamer Group", "APTA" or the "Company")**

**Result of General Meeting and Board Changes**

Aptamer Group (AIM:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce that, further to the Company's announcement on 24 July 2024 and subsequent announcement on 1 August 2024, at its General Meeting held today, all Resolutions were passed.

Accordingly, all of the proposals set out in the Company's circular dated 24 July 2024 (the "Circular") and the announcement made on 1 August 2024 will proceed.

**Board Changes**

With effect from Admission (scheduled for 8:00 a.m. on 14 August 2024), the board will comprise:

- Dr Adam Hargreaves (Non-Executive Chairman)
- Dr Arron Tolley (Chief Executive Officer)
- Dr David Bunka (Chief Scientific Officer)
- Andrew Rapson (Chief Financial Officer)

The resignations of Stephen Hull (Executive Chairman) and Dean Fielding (Non-Executive Director) take effect from Admission.

The Company would like to take the opportunity to thank Stephen and Dean for their contribution and commitment over the last 12 months.

The Company is still to looking to appoint another Non-Executive Director at the earliest opportunity.

For further information, please contact:

<b>Aptamer Group plc</b>	+44 (0) 1904 217 404
Dr Arron Tolley	
<b>SPARK Advisory Partners Limited - Nominated Adviser</b>	+44 (0) 20 3368 3550
Andrew Emmott / Adam Dawes	
<b>Turner Pope Investments (TPI) Ltd - Broker</b>	+44 (0) 20 3657 0050
James Pope / Andrew Thacker	

Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the Company's announcement dated 31 July 2023.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

**About Aptamer Group plc**

[Aptamer](#) develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over \$170 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.

**Further Disclosure regarding Andrew Rapson**

**Andrew Rapson - Chief Financial Officer (aged 42 years)**

Andrew Rapson is a qualified chartered accountant with an accountancy career spanning over 20 years. He has worked in an AIM environment for the last 9 years, formerly as Head of Finance for Hunters Property plc before joining Aptamer Group plc in 2022.

With effect from Second Admission, Andrew Rapson will be interested in 3,000,000 ordinary Shares representing 0.16% of the issued share capital.

Save as disclosed above, there are no further disclosures in relation to the appointment of Andrew Rapson pursuant to Schedule 2(g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMPJMBTMTABBAI